Skip to Content

Versed (midazolam) Disease Interactions

There are 12 disease interactions with Versed (midazolam):

Major

Benzodiazepines (Includes Versed) ↔ Acute Alcohol Intoxication

Severe Potential Hazard, High plausibility

Applies to: Acute Alcohol Intoxication

The use of benzodiazepines with alcohol is not recommended. Patients with acute alcohol intoxication exhibit depressed vital signs. The central nervous system depressant effects of benzodiazepines may be additive with those of alcohol, and severe respiratory depression and death may occur. Therapy with benzodiazepines should be administered cautiously in patients who might be prone to acute alcohol intake.

References

  1. "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. "Product Information. Doral (quazepam)." Wallace Laboratories, Cranbury, NJ.
  3. "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.
  4. "Product Information. ProSom (estazolam)." Abbott Pharmaceutical, Abbott Park, IL.
  5. "Product Information. Dalmane (flurazepam)." Roche Laboratories, Nutley, NJ.
  6. "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical, Abbott Park, IL.
  7. "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  8. "Product Information. Versed (midazolam)." Roche Laboratories, Nutley, NJ.
  9. "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  10. "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  11. "Product Information. Librium (chlordiazepoxide)." Roche Laboratories, Nutley, NJ.
  12. "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  13. "Product Information. Klonopin (clonazepam)." Roche Laboratories, Nutley, NJ.
View all 13 references
Major

Benzodiazepines (Includes Versed) ↔ Closed-Angle Glaucoma

Severe Potential Hazard, Low plausibility

Applies to: Glaucoma/Intraocular Hypertension

The manufacturers consider the use of benzodiazepines to be contraindicated in patients with acute angle-closure glaucoma or untreated open-angle glaucoma. These agents do not possess anticholinergic activity but have very rarely been associated with increased intraocular pressure.

References

  1. "Product Information. Klonopin (clonazepam)." Roche Laboratories, Nutley, NJ.
  2. "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  3. "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  4. "Product Information. Doral (quazepam)." Wallace Laboratories, Cranbury, NJ.
  5. "Product Information. Dalmane (flurazepam)." Roche Laboratories, Nutley, NJ.
  6. "Product Information. ProSom (estazolam)." Abbott Pharmaceutical, Abbott Park, IL.
  7. "Product Information. Versed (midazolam)." Roche Laboratories, Nutley, NJ.
  8. "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical, Abbott Park, IL.
  9. "Product Information. Librium (chlordiazepoxide)." Roche Laboratories, Nutley, NJ.
  10. "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  11. "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  12. "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  13. Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects 5th" Boston, MA: Butterworth-Heinemann (2001):
  14. "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.
View all 14 references
Major

Benzodiazepines (Includes Versed) ↔ Respiratory Depression

Severe Potential Hazard, High plausibility

Applies to: Pulmonary Impairment, Asphyxia, Respiratory Arrest

Benzodiazepines may cause respiratory depression and apnea, usually when given in high dosages and/or by intravenous administration. However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders. Therapy with benzodiazepines should be administered cautiously in these patients. Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used. Benzodiazepines, especially injectable formulations, should generally be avoided in patients with sleep apnea, severe respiratory insufficiency, or hypoxia.

References

  1. Cohen S, Khan A "Respiratory distress with use of lorazepam in mania." J Clin Psychopharmacol 7 (1987): 199-200
  2. Eldridge PR, Punt JA "Risks associated with giving benzodiazepines to patients with acute neurological injuries." Br Med J 300 (1990): 1189-90
  3. Berggren L, Eriksson I, Mollenholt P, Sunzel M "Changes in respiratory pattern after repeated doses of diazepam and midazolam in healthy subjects." Acta Anaesthesiol Scand 31 (1987): 667-72
  4. "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  5. Man GC, Hsu K, Sproule BJ "Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease." Chest 90 (1986): 832-6
  6. "Product Information. ProSom (estazolam)." Abbott Pharmaceutical, Abbott Park, IL.
  7. "Product Information. Dalmane (flurazepam)." Roche Laboratories, Nutley, NJ.
  8. Skatrud JB, Badr S, Begle RL, Juan D "Ventilatory response to single, high dose estazolam in healthy humans." J Clin Pharmacol 30 (1990): 543-8
  9. Yakel DL, Jr Whittaker SE, Elstad MR "Midazolam-induced angioedema and bronchoconstriction." Crit Care Med 20 (1992): 307-8
  10. Iber FL, Livak A, Kruss DM "Apnea and cardiopulmonary arrest during and after endoscopy." J Clin Gastroenterol 14 (1992): 109-13
  11. "Product Information. Klonopin (clonazepam)." Roche Laboratories, Nutley, NJ.
  12. "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  13. Pierce MW, Shu VS, Groves LJ "Safety of estazolam. The United States clinical experience." Am J Med 88 (1990): s12-7
  14. "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical, Abbott Park, IL.
  15. Sullivan RJ, Jr "Respiratory depression requiring ventilatory support following 0.5 mg of triazolam." J Am Geriatr Soc 37 (1989): 450-2
  16. "Product Information. Doral (quazepam)." Wallace Laboratories, Cranbury, NJ.
  17. "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.
  18. Berry RB, Kouchi K, Bower J, Prosise G, Light RW "Triazolam in patients with obstructive sleep apnea." Am J Respir Crit Care Med 151 (1995): 450-4
  19. "Product Information. Versed (midazolam)." Roche Laboratories, Nutley, NJ.
  20. Mendelson WB, Weingartner H, Greenblatt DJ, Garnett D, Gillin JC "A clinical study of flurazepam." Sleep 5 (1982): 350-60
  21. "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  22. Munoz HR, Dagnino JA, Rufs JA, Bugedo GJ "Benzodiazepine premedication causes hypoxemia during spinal anesthesia in geriatric patients." Reg Anesth 17 (1992): 139-42
  23. "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  24. "Product Information. Librium (chlordiazepoxide)." Roche Laboratories, Nutley, NJ.
  25. Taylor JW, Simon KB "Possible intramuscular midazolam-associated cardiorespiratory arrest and death." DICP 24 (1990): 695-7
  26. Murphy PJ, Erskine R, Langton JA "The effect of intravenously administered diazepam, midazolam and flumazenil on the sensitivity of upper airway reflexes." Anaesthesia 49 (1994): 105-10
  27. Model DG, Berry DJ "Effects of chlordiazepoxide in respiratory failure due to chronic bronchitis." Lancet 2 (1974): 869-70
  28. Dixon D "Respiratory depression following midazolam." Anaesthesia 40 (1985): 922
  29. "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  30. Donaldson D, Gibson G "System complications with intravenous diazepam." Oral Surg Oral Med Oral Patho 49 (1980): 126-30
View all 30 references
Major

Benzodiazepines (Includes Versed) ↔ Seizures

Severe Potential Hazard, Moderate plausibility

Applies to: Seizures

The use of benzodiazepines in patients with seizure disorders may increase the incidence or precipitate the onset of generalized tonic-clonic seizures (grand mal). Appropriate anticonvulsant medication might need to be initiated or the dosage increased. Abrupt cessation of benzodiazepine therapy may precipitate seizures and other withdrawal symptoms, particularly after prolonged use and/or excessive dosages. Status epilepticus may occur in patients with a history of seizures withdrawn rapidly from benzodiazepine therapy. Following chronic administration, cessation of benzodiazepine therapy should occur gradually with incrementally reduced dosages. Patients should be advised not to discontinue medication without first consulting with the physician.

References

  1. Browne JL, Hauge KJ "A review of alprazolam withdrawal." Drug Intell Clin Pharm 20 (1986): 837-41
  2. Schneider LS, Syapin PJ, Pawluczyk S "Seizures following triazolam withdrawal despite benzodiazepine treatment." J Clin Psychiatry 48 (1987): 418-9
  3. Tien AY, Gujavarty KS "Seizure following withdrawal from triazolam." Am J Psychiatry 142 (1985): 1516-7
  4. Berlin RM, Conell LJ "Withdrawal symptoms after long-term treatment with therapeutic doses of flurazepam: a case report." Am J Psychiatry 140 (1983): 488-90
  5. "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  6. Finley PR, Nolan PE, Jr "Precipitation of benzodiazepine withdrawal following sudden discontinuation of midazolam." DICP 23 (1989): 151-2
  7. "Product Information. ProSom (estazolam)." Abbott Pharmaceutical, Abbott Park, IL.
  8. Kales A, Bixler EO, Soldatos CR, Jacoby JA, Kales JD "Lorazepam: effects on sleep and withdrawal phenomena." Pharmacology 32 (1986): 121-30
  9. Hauser P, Devinsky O, De Bellis M, Theodore WH, Post RM "Benzodiazepine withdrawal delirium with catatonic features. Occurrence in patients with partial seizure disorders." Arch Neurol 46 (1989): 696-9
  10. "Product Information. Doral (quazepam)." Wallace Laboratories, Cranbury, NJ.
  11. Ryan GP, Boisse NR "Experimental induction of benzodiazepine tolerance and physical dependence." J Pharmacol Exp Ther 226 (1983): 100-7
  12. "Product Information. Dalmane (flurazepam)." Roche Laboratories, Nutley, NJ.
  13. "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.
  14. MacKinnon GL, Parker WA "Benzodiazepine withdrawal syndrome: a literature review and evaluation." Am J Drug Alcohol Abuse 9 (1982): 19-33
  15. Busto U, Sellers EM, Naranjo CA, et al "Withdrawal reaction after long-term therapeutic use of benzodiazepines." N Engl J Med 315 (1986): 854-9
  16. Ananth J "Abstinence syndrome from therapeutic doses of oxazepam." Can J Psychiatry 28 (1983): 592
  17. "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical, Abbott Park, IL.
  18. Petursson H, Lader MH "Benzodiazepine dependence." Br J Addict 76 (1981): 133-45
  19. Howe JG "Lorazepam withdrawal seizures." Br Med J 280 (1980): 1163-4
  20. "Product Information. Versed (midazolam)." Roche Laboratories, Nutley, NJ.
  21. "Product Information. Librium (chlordiazepoxide)." Roche Laboratories, Nutley, NJ.
  22. "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  23. Ghadirian AM, Gauthier S, Wong T "Convulsions in patients abruptly withdrawn from clonazepam while receiving neuroleptic medication ." Am J Psychiatry 144 (1987): 686
  24. Bond WS, Schwartz M "Withdrawal reactions after long-term treatment with flurazepam." Clin Pharm 3 (1984): 316-8
  25. Alvarez N, Hartford E, Doubt C "Epileptic seizures induced by clonazepam." Clin Electroencephalogr 12 (1981): 57-65
  26. Roy-Byrne PP, Sullivan MD, Cowley DS, Ries RK "Adjunctive treatment of benzodiazepine discontinuation syndromes - a review." J Psychiatr Res 27 Suppl (1993): 143-53
  27. "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  28. Frattola L, Garreau M, Piolti R, Bassi S, Albizzati MG, Borghi C, Morselli PL "Comparison of the efficacy, safety and withdrawal of alpidem and alprazolam in anxious patients." Br J Psychiatry 165 (1994): 94-100
  29. Specht U, Boenigk HE, Wolf P "Discontinuation of clonazepam after long-term treatment." Epilepsia 30 (1989): 458-63
  30. Patterson WM "Triazolam withdrawal." J Clin Psychiatry 49 (1988): 369
  31. Wilbur R, Kulik AV "Abstinence syndrome from therapeutic doses of oxazepam." Can J Psychiatry 28 (1983): 298-300
  32. Robinson GM, Sellers EM "Diazepam withdrawal seizures." Can Med Assoc J 126 (1982): 944-5
  33. "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  34. Hersch EL, Billings RF "Acute confusional state with status petit mal as a withdrawal syndrome: and five year follow-up." Can J Psychiatry 33 (1988): 157-9
  35. "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  36. "Product Information. Klonopin (clonazepam)." Roche Laboratories, Nutley, NJ.
View all 36 references
Major

Benzodiazepines (Iv/Im) (Includes Versed) ↔ Prolonged Hypotension

Severe Potential Hazard, High plausibility

Applies to: Shock, Altered Consciousness

Benzodiazepines should not be administered by injection to patients in shock or coma. The hypnotic and hypotensive effects of these agents may be prolonged and intensified in such patients.

References

  1. "Product Information. Librium (chlordiazepoxide)." Roche Laboratories, Nutley, NJ.
  2. "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  3. "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.
  4. "Product Information. Versed (midazolam)." Roche Laboratories, Nutley, NJ.
View all 4 references
Major

Mdvs (Includes Versed) ↔ Prematurity

Severe Potential Hazard, Moderate plausibility

Applies to: Prematurity/Underweight in Infancy

Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative. Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight. When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants. Thus, single-dose formulations should always be used in infants whenever possible. However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated. The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns. However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered. The level at which toxicity may occur is unknown.

References

  1. "Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. ""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997): 268-78
  3. "Product Information. Nuromax (doxacurium)." Glaxo Wellcome, Research Triangle Park, NC.
  4. "Product Information. Mesnex (mesna)." Bristol-Myers Squibb, Princeton, NJ.
  5. "Product Information. Tracrium (atracurium)." Glaxo Wellcome, Research Triangle Park, NC.
  6. "Product Information. Mivacron (mivacurium)." Glaxo Wellcome, Research Triangle Park, NC.
View all 6 references
Major

Midazolam (Includes Versed) ↔ Cns Depression/Electrolyte Disturbances

Severe Potential Hazard, Moderate plausibility

Applies to: Acute Alcohol Intoxication, Electrolyte Abnormalities

Injectable midazolam should not be administered in adult or pediatric patients in shock or coma or in acute alcohol intoxication with depression of vital signs. Particular care should be exercised in the use of intravenous midazolam in patients with uncompensated acute illnesses, such as severe fluid or electrolyte disturbances.

Major

Midazolam (Includes Versed) ↔ Congestive Heart Failure

Severe Potential Hazard, High plausibility

Applies to: Congestive Heart Failure

In patients with congestive heart failure, there appears to be a two-fold increase in the elimination half-life, a 25% decrease in the plasma clearance, and a 40% increase in the volume of distribution of midazolam. Therapy with midazolam should be administered cautiously at reduced initial dosages in patients with congestive heart failure, particularly if they are elderly. The possibility of profound and/or prolonged effect should be considered.

References

  1. "Product Information. Versed (midazolam)." Roche Laboratories, Nutley, NJ.
  2. Patel IH, Soni PP, Fukuda EK, Smith DF, Leier CV, Boudoulas H "The pharmacokinetics of midazolam in patients with congestive heart failure." Br J Clin Pharmacol 29 (1990): 565-9
Major

Midazolam (Includes Versed) ↔ Renal/Liver Disease

Severe Potential Hazard, High plausibility

Applies to: Liver Disease, Renal Dysfunction

Midazolam is metabolized by the liver, and the metabolites are excreted in the urine. Reduced drug clearance and prolonged elimination half-life of parent drug and metabolites have been reported in patients with renal and/or hepatic impairment. Therapy with midazolam should be administered cautiously at reduced initial dosages in such patients. The possibility of profound and/or prolonged effect should be considered.

References

  1. "Product Information. Versed (midazolam)." Roche Laboratories, Nutley, NJ.
  2. MacGilchrist AJ, Birnie GG, Cook A, Scobie G, Murray T, Watkinson G, Brodie MJ "Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis." Gut 27 (1986): 190-5
  3. Trouvin JH, Farinotti R, Haberer JP, et al "Pharmacokinetics of midazolam in anaesthetized cirrhotic patients." Br J Anaesth 60 (1988): 762-7
  4. Vinik HR, Reves JG, Greenblatt DJ, Abernethy DR, Smith LR "The pharmacokinetics of midazolam in chronic renal failure patients." Anesthesiology 59 (1983): 390-4
  5. Calvo R, Suarez E, Rodriguez-Sasiain JM, Martinez I "The influence of renal failure on the kinetics of intravenous midazolam: an "in vitro" and "in vivo" study." Res Commun Chem Pathol Pharmacol 78 (1992): 311-20
View all 5 references
Moderate

Benzodiazepines (Includes Versed) ↔ Depression

Moderate Potential Hazard, Moderate plausibility

Applies to: Psychosis

Benzodiazepines depress the central nervous system and may cause or exacerbate mental depression and cause suicidal behavior and ideation. Episodes of mania and hypomania have also been reported in depressed patients treated with some of these agents. Therapy with benzodiazepines should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

References

  1. "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  3. "Product Information. Klonopin (clonazepam)." Roche Laboratories, Nutley, NJ.
  4. "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical, Abbott Park, IL.
  5. "Product Information. Librium (chlordiazepoxide)." Roche Laboratories, Nutley, NJ.
  6. "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  7. "Product Information. Dalmane (flurazepam)." Roche Laboratories, Nutley, NJ.
  8. "Product Information. ProSom (estazolam)." Abbott Pharmaceutical, Abbott Park, IL.
  9. "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  10. "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  11. "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.
  12. "Product Information. Doral (quazepam)." Wallace Laboratories, Cranbury, NJ.
View all 12 references
Moderate

Benzodiazepines (Includes Versed) ↔ Obesity

Moderate Potential Hazard, High plausibility

Applies to: Obesity

The plasma half-lives of benzodiazepines may be prolonged in obese patients, presumably due to increased distribution into fat. Marked increases in distribution (> 100%) have been reported for diazepam and midazolam, and moderate increases (25% to 100%) for alprazolam, lorazepam, and oxazepam. Therapy with benzodiazepines should be administered cautiously in obese patients, with careful monitoring of CNS status. Longer dosing intervals may be appropriate. When dosing by weight, loading doses should be based on actual body weight, while maintenance dose should be based on ideal body weight to avoid toxicity.

References

  1. "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical, Abbott Park, IL.
  2. "Product Information. Librium (chlordiazepoxide)." Roche Laboratories, Nutley, NJ.
  3. "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  4. "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  5. "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  6. "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  7. "Product Information. Klonopin (clonazepam)." Roche Laboratories, Nutley, NJ.
  8. "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  9. "Product Information. ProSom (estazolam)." Abbott Pharmaceutical, Abbott Park, IL.
  10. "Product Information. Versed (midazolam)." Roche Laboratories, Nutley, NJ.
  11. "Product Information. Doral (quazepam)." Wallace Laboratories, Cranbury, NJ.
  12. "Product Information. Dalmane (flurazepam)." Roche Laboratories, Nutley, NJ.
  13. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
  14. "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.
View all 14 references
Moderate

Benzodiazepines (Includes Versed) ↔ Paradoxical Reactions

Moderate Potential Hazard, Moderate plausibility

Applies to: Psychosis, Hyperkinetic Syndrome of Childhood

Paradoxical reactions, including excitability, irritability, aggressive behavior, agitation, nervousness, hostility, anxiety, sleep disturbances, nightmares and vivid dreams, have been reported with the use of benzodiazepines in psychiatric patients and pediatric patients with hyperactive aggressive disorders. Such patients should be monitored for signs of paradoxical stimulation during therapy with benzodiazepines. The manufacturers do not recommend the use of benzodiazepines for the treatment of psychosis.

References

  1. "Product Information. Dalmane (flurazepam)." Roche Laboratories, Nutley, NJ.
  2. "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.
  3. White MC, Silverman JJ, Harbison JW "Psychosis associated with clonazepam therapy for blepharospasm." J Nerv Ment Dis 170 (1982): 117-9
  4. Fiset L, Milgrom P, Beirne OR, Roy-Byrne P "Disinhibition of behaviors with midazolam: report of a case." J Oral Maxillofac Surg 50 (1992): 645-9
  5. Marchevsky S, Isaacs G, Nitzan I "Behavioral disinhibition with clonazepam." Gen Hosp Psychiatry 10 (1988): 447
  6. Fava M, Borofsky GF "Sexual disinhibition during treatment with a benzodiazepine: a case report." Int J Psychiatry Med 21 (1991): 99-104
  7. Goodman WK, Charney DS "A case of alprazolam, but not lorazepam, inducing manic symptoms." J Clin Psychiatry 48 (1987): 117-8
  8. Cunningham TA "Letter: Adverse reaction to flurazepam." Can Med Assoc J 112 (1975): 805
  9. "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical, Abbott Park, IL.
  10. Schogt B, Conn D "Paranoid symptoms associated with triazolam." Can J Psychiatry 30 (1985): 462-3
  11. "Product Information. Librium (chlordiazepoxide)." Roche Laboratories, Nutley, NJ.
  12. Binder RL "Three case reports of behavioral disinhibition with clonazepam." Gen Hosp Psychiatry 9 (1987): 151-3
  13. Lobo BL, Miwa LJ "Midazolam disinhibition reaction." Drug Intell Clin Pharm 22 (1988): 725
  14. Weilburg JB, Sachs G, Falk WE "Triazolam-induced brief episodes of secondary mania in a depressed patient." J Clin Psychiatry 48 (1987): 492-3
  15. "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  16. Cohen LS, Rosenbaum JF "Clonazepam: new uses and potential problems." J Clin Psychiatry 48 (1987): 50-6
  17. Karch FE "Rage reaction associated with clorazepate dipotassium." Ann Intern Med 91 (1979): 61-2
  18. "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  19. "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  20. Dorevitch A "Mania associated with clonazepam." DICP 25 (1991): 938-9
  21. Koczerginski D, Kennedy SH, Swinson RP "Clonazepam and lithium--a toxic combination in the treatment of mania?" Int Clin Psychopharmacol 4 (1989): 195-9
  22. Edwards JG, Inman WH, Pearce GL, Rawson NS "Prescription-event monitoring of 10,895 patients treated with alprazolam." Br J Psychiatry 158 (1991): 387-92
  23. Pollack MH "Clonazepam: a review of open clinical trials." J Clin Psychiatry 48 (1987): 12-5
  24. Rush CR, Higgins ST, Hughes JR, Bickel WK "A comparison of the acute behavioral effects of triazolam and temazepam in normal volunteers." Psychopharmacology (Berl) 112 (1993): 407-14
  25. "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  26. Wysowski DK, Barash D "Adverse behavioral reactions attributed to triazolam in the Food and Drug Administration's Spontaneous Reporting System." Arch Intern Med 151 (1991): 2003-8
  27. Rothschild AJ "Disinhibition, amnestic reactions, and other adverse reactions secondary to triazolam: a review of the literature." J Clin Psychiatry 53 (1992): 69-79
  28. French AP "Dangerously aggressive behavior as a side effect of alprazolam." Am J Psychiatry 146 (1989): 276
  29. "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  30. "Product Information. ProSom (estazolam)." Abbott Pharmaceutical, Abbott Park, IL.
  31. Bixler EO, Kales A, Brubaker BH, Kales JD "Adverse reactions to benzodiazepine hypnotics: spontaneous reporting system." Pharmacology 35 (1987): 286-300
  32. "Product Information. Klonopin (clonazepam)." Roche Laboratories, Nutley, NJ.
  33. Viscott DS "Chlordiazepoxide and hallucinations. Report of cases." Arch Gen Psychiatry 19 (1968): 370-6
  34. "Product Information. Versed (midazolam)." Roche Laboratories, Nutley, NJ.
  35. "Product Information. Doral (quazepam)." Wallace Laboratories, Cranbury, NJ.
View all 35 references

Versed (midazolam) drug Interactions

There are 934 drug interactions with Versed (midazolam)

Versed (midazolam) alcohol/food Interactions

There are 2 alcohol/food interactions with Versed (midazolam)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide